@Article{Pogorzelska2016,
journal="Clinical and Experimental Hepatology",
issn="2392-1099",
volume="2",
number="2",
year="2016",
title="Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection",
abstract="Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r ± DSV ± RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r ± DSV ± RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r ± DSV ± RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.",
author="Pogorzelska, Joanna
and Flisiak, Robert",
pages="34--37",
doi="10.5114/ceh.2016.60247",
url="http://dx.doi.org/10.5114/ceh.2016.60247"
}